Skip to content
    Reviews

    PPI Co-Administration for Cisplatin-Induced Nephrotoxicity

    Pakkhesal et alSupportive Care in Cancer

    PPI Co-Administration for Cisplatin-Induced Nephrotoxicity
    Cisplatin chemotherapy is frequently limited by dose-dependent nephrotoxicity. While proton pump inhibitors (PPIs) have been hypothesized to mitigate this toxicity via renal OCT2 transporter inhibition, independent literature has linked PPI exposure to acute kidney injury (AKI). To evaluate this relationship, a systematic review registered in PROSPERO (CRD420251087906) synthesized clinical evidence evaluating cisplatin regimens with versus without concurrent PPI therapy across PubMed, Embase, Web of Science, and Scopus. Due to extreme clinical, methodological, and statistical heterogeneity, investigators conducted a narrative synthesis rather than a quantitative meta-analysis, evaluating study quality via the Cochrane RoB2 and ROBINS-I tools.
    The review evaluated eight studies comprising 1062 participants, including two randomized controlled trials (RCTs) and six non-randomized studies. Findings were conflicting across the analyzed cohorts. Two retrospective studies reported a significant nephroprotective effect. One RCT reported a trend toward renal protection in its primary endpoint (0% nephrotoxicity with high-dose pantoprazole vs 25% in controls, p = 0.078) along with significant suppression of renal injury biomarkers. In contrast, one prospective cohort identified PPI therapy as an independent risk factor for AKI (OR 2.78; p = 0.010) as well as worse post-treatment eGFR outcomes. Four additional studies—consisting of one crossover RCT and three retrospective cohorts—observed no statistically significant association between PPI administration and renal endpoints.
    The authors concluded that current evidence does not allow a clear conclusion regarding the efficacy or safety of PPI co-administration for preventing cisplatin nephrotoxicity. Although PPIs may reduce gastrointestinal toxicity, caution is advised given the potential signal for AKI harm, and further high-quality RCTs are needed to provide a definitive answer.

    Key Takeaways

    • In one prospective cohort, PPI co-administration was identified as an independent risk factor for acute kidney injury (OR 2.78; p = 0.010) and was associated with worse post-treatment eGFR outcomes.
    • Across eight studies (n = 1062), renal outcomes were conflicting: one RCT showed a trend toward protection with high-dose pantoprazole (0% nephrotoxicity vs 25% in controls; p = 0.078) alongside significant biomarker suppression, two retrospective cohorts reported a significant nephroprotective effect, and four studies found no statistically significant association.
    Read the original sourceSupportive Care in Cancer